Genomic and phenotypic analysis of BRCA2mutated breast cancers reveals co-occurring changes linked to progression

被引：0
|
作者：
Olafur A Stefansson
Jon G Jonasson
Kristrun Olafsdottir
Hordur Bjarnason
Oskar Th Johannsson
Sigridur K Bodvarsdottir
Sigridur Valgeirsdottir
Jorunn E Eyfjord
机构：
[1] University of Iceland,Cancer Research Laboratory, Faculty of Medicine
[2] Landspitali University Hospital,Department of Pathology
[3] Landspitali University Hospital,Department of Oncology
[4] The Icelandic Cancer Registry,undefined
[5] Roche NimbleGen,undefined
[6] Inc.,undefined
来源：
Breast Cancer Research | / 13卷
关键词：
BRCA2 Mutation Carrier; BRCA2 Carrier; Sporadic Breast Cancer; Luminal Subtype; Familial Pancreatic Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 24 条
  • [21] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Jayanthan, Harikrishna Sekar
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Sheehan, Jonathan H.
    Koch, James P.
    Sudhan, Dhivya R.
    Brewer, Monica Red
    Servetto, Alberto
    He, Jie
    Miller, Vincent A.
    Lalani, Alshad S.
    Meiler, Jens
    Arteaga, Carlos L.
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Longitudinal pro fi ling identi fi es co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer
    Harvey-Jones, E.
    Raghunandan, M.
    Robbez-Masson, L.
    Magraner-Pardo, L.
    Alaguthurai, T.
    Yablonovitch, A.
    Yen, J.
    Xiao, H.
    Brough, R.
    Frankum, J.
    Song, F.
    Yeung, J.
    Savy, T.
    Gulati, A.
    Alexander, J.
    Kemp, H.
    Starling, C.
    Konde, A.
    Marlow, R.
    Cheang, M.
    Proszek, P.
    Hubank, M.
    Cai, M.
    Trendell, J.
    Lu, R.
    Liccardo, R.
    Ravindran, N.
    Llop-Guevara, A.
    Rodriguez, O.
    Balmana, J.
    Lukashchuk, N.
    Dorschner, M.
    Drusbosky, L.
    Roxanis, I.
    Serra, V.
    Haider, S.
    Pettitt, S. J.
    Lord, C. J.
    Tutt, A. N. J.
    ANNALS OF ONCOLOGY, 2024, 35 (04) : 364 - 380
  • [23] Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Marra, A.
    Gazzo, A.
    Gupta, A.
    Selenica, P.
    Da Silva, E. M.
    Pareja, F.
    Pei, X.
    Zhu, Y.
    Razavi, P.
    Safonov, A.
    Ferraro, E.
    Harris, R.
    Riaz, N.
    Reis-Filho, J. S.
    Chandarlapaty, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S632
  • [24] Genomic and transcriptomic analysis reveals known and novel resistance mechanisms to CDK4/6 inhibitors and sensitivity factors for the response to triplet therapy (palbociclib plus everolimus plus exemestane) in a phase I/IIb study in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i)
    Zanudo, Jorge Gomez Tejeda
    Barroso-Sousa, Romualdo
    Jain, Esha
    Buendia-Buendia, Jorge
    Li, Tianyu
    Tayob, Nabihah
    Rees, Rebecca
    Pereslete, Alyssa
    Ferreira, Arlindo R.
    Abravanel, Daniel L.
    Helvie, Karla
    Partridge, Ann H.
    Overmoyer, Beth
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
123